Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

mRNA-3745

Phase 2RNA therapy

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Glycogen Storage DiseaseActive, not recruiting

Glycogen Storage DiseasePhase 2

Active, not recruiting

Timeline

Expected Milestones

Q4 2026

Phase 1/2Active, not recruiting

Glycogen Storage Disease

NCT05095727

Clinical

Trials by Indication[1]

Glycogen Storage Disease1 trial

A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)

Active, not recruiting· Moderna logo

Moderna·Phase 1/2·NCT05095727·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for mRNA-3745. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mRNA-3745 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mRNA-3745. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Moderna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 2[1]
Company: Moderna

Related News